ArticleMolecular neurobiology2019
A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs.
Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 107 citations in OpenAlex.
- Integration of machine learning to develop a disulfidptosis model for predicting glioma prognosis, immunotherapy response, and drug.iScience · 2026Article
- Establishment of a novel gene panel for prognosis assessment in patients with lower grade glioma.Medicine · 2026Article
- The aggrephagy-related gene TUBA1B influences clinical outcomes in glioma patients by regulating the cell cycle.Frontiers in oncology · 2025Article
- Article
- Machine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma.Discover oncology · 2024Article
- Radiomics Analysis of Quantitative Maps from Synthetic MRI for Predicting Grades and Molecular Subtypes of Diffuse Gliomas.Clinical neuroradiology · 2024Article
- A first comprehensive analysis of Transcribed Ultra Conserved Regions uncovers important regulatory functions of novel non-coding transcripts in gliomas.Research square · 2024Article
- Article
- Article
- The Potential Significance of the EMILIN3 Gene in Augmenting the Aggressiveness of Low-Grade Gliomas is Noteworthy.Cancer management and research · 2024Article
- Prognostic value of four immune-related genes in lower-grade gliomas: a biomarker discovery study.Frontiers in genetics · 2024Article
- MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma.Aging · 2023Article
- Article
- TAF1D Functions as a Novel Biomarker in Osteosarcoma.Journal of Cancer · 2023Article
- A Novel Prognostic Pyroptosis-Related Gene Signature Correlates to Oxidative Stress and Immune-Related Features in Gliomas.Oxidative medicine and cellular longevity · 2023Article
- Intra-operative applications of augmented reality in glioma surgery: a systematic review.Frontiers in surgery · 2023Review
- Mutation-derived, genomic instability-associated lncRNAs are prognostic markers in gliomas.PeerJ · 2023Article
- Inefficient splicing of long non-coding RNAs is associated with higher transcript complexity in human and mouse.RNA biology · 2023Article
- Identification of cuproptosis-related lncRNAs for prognosis and immunotherapy in glioma.Journal of cellular and molecular medicine · 2022Article
- Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways.International journal of molecular sciences · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Diffuse low-grade and intermediate-grade gliomas (together known as lower grade gliomas, WHO grade II and III) develop in the supporting glial cells of brain and are the most common types of primary brain tumor. Despite a better prognosis for lower grade gliomas, 70% of patients undergo high-grade transformation within 10 years, stressing the importance of better prognosis. Long non-coding RNAs (lncRNAs) are gaining attention as potential biomarkers for cancer diagnosis and prognosis. We have developed a computational model, UVA8, for prognosis of lower grade gliomas by combining lncRNA expression, Cox regression, and L1-LASSO penalization. The model was trained on a subset of patients in TCGA. Patients in TCGA, as well as a completely independent validation set (CGGA) could be dichotomized based on their risk score, a linear combination of the level of each prognostic lncRNA weighted by its multivariable Cox regression coefficient. UVA8 is an independent predictor of survival and outperforms standard epidemiological approaches and previous published lncRNA-based predictors as a survival model. Guilt-by-association studies of the lncRNAs in UVA8, all of which predict good outcome, suggest they have a role in suppressing interferon-stimulated response and epithelial to mesenchymal transition. The expression levels of eight lncRNAs can be combined to produce a prognostic tool applicable to diverse populations of glioma patients. The 8 lncRNA (UVA8) based score can identify grade II and grade III glioma patients with poor outcome, and thus identify patients who should receive more aggressive therapy at the outset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.